Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling

Fig. 1

RNA-sequence analysis of ATF3 in C4–2. (A) C4–2 cells were treated with 5 μM ASC-J9® (or DMSO), or infected with shAR (or Scr), or 10 μM Enz (or DMSO), followed by RNA-seq. In the heat map, red lines are shown as high expressed genes, green lines are shown as low expressed genes, J9/DMSO = ASC-J9® vs. DMSO, shAR/scr = knockdown AR vs. scramble, ENZ/DMSO = Enz vs. DMSO. b The rationale of screening out the unique ASC-J9® tumor suppressor genes. c Functional analysis via gene ontology selected out 11 cancer suppression genes including ATF3. Left chart shows 105 ASC-J9® specifically upregulated genes GO analysis. Right chart shows 25 ASC-J9® specifically upregulated genes involved in Biological regulation. Different colors represent different Biological Process. The color labeled with percentage includes ATF3. d Isolating RNA expression data from RNA-seq (see a), ASC-J9® uniquely increases ATF3 expression compared with Enz and shAR groups. e In C4–2 (upper panels) and CWR22Rv1 (lower panels) cells, qRT-PCR results reveal ATF3 expression level in 5 μM ASC-J9® treatment group was significantly higher than 10 μM Enz treatment and shAR transduced group. Data represent the Mean ± SEM, **p < 0.01, ns = no significance, by Unpaired t-test

Back to article page
\